Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexicon Pharmaceuticals, Inc. - Common Stock
(NQ:
LXRX
)
1.760
+0.200 (+12.82%)
Official Closing Price
Updated: 4:00 PM EST, Jan 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexicon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
February 18, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
January 29, 2025
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
↗
January 28, 2025
Via
Benzinga
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
January 21, 2025
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations For Lexicon Pharmaceuticals's Future
↗
December 23, 2024
Via
Benzinga
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
↗
November 13, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Lexicon Appoints Scott Coiante as Chief Financial Officer
January 02, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
December 20, 2024
Confirms Previously Disclosed and Anticipated FDA Decision
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Preview: Lexicon Pharmaceuticals's Earnings
↗
November 11, 2024
Via
Benzinga
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
↗
November 05, 2024
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
↗
September 27, 2024
Via
Benzinga
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts
↗
September 03, 2024
Via
Benzinga
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
November 26, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Participate in December Investor Conferences
November 25, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
November 22, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Appoints Ivan H. Cheung to Board of Directors
November 20, 2024
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals
↗
August 13, 2024
Via
Benzinga
5 Analysts Have This To Say About Lexicon Pharmaceuticals
↗
August 02, 2024
Via
Benzinga
What You Missed On Wall Street This Past Friday
↗
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
↗
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
↗
November 01, 2024
Via
Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
↗
November 01, 2024
Via
Benzinga
Topics
Stocks
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
↗
November 01, 2024
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 01, 2024
Via
Benzinga
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
↗
October 23, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
↗
October 17, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
